Abstract: Tumor-draining lymph node，abbreviated as TDLN， refers to the lymph node affected by tumor cells through lymphatic ducts， including various types of immune cells， like nature killer cells， T cells， antigen presenting cells and B cells. Because of the presence of these immune cells and the unique location of TDLN located downstream of the tumor， TDLN becomes an important site of anti-tumor immune response. However， TDLN， often developing immune tolerance to the tumor， becomes the transfer relay station of tumor cells to other tissues. In the immunotherapy of TDLN， except vitro-activate cell therapy and in vivo-activated cell therapy， some new treatments， such as targeted therapy， are becoming the focus of research. This article reviews the immunological properties of TDLN， and the mechanism and research progress of TDLN related immunotherapy.